TITLE

Leczenie podtrzymujÄ…ce remisjÄ™ w nieswoistych zapaleniach jelit

AUTHOR(S)
Neubauer, Katarzyna; Paradowski, Leszek
PUB. DATE
March 2010
SOURCE
Gastroenterologia Polska / Gastroenterology;2010, Vol. 17 Issue 2, p129
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Maintenance therapy in inflammatory bowel disease (IBD) involves 5′-aminosalicylate derivatives, immunosuppressive drugs (azathioprine, 6-mercaptopurine, methotrexate), and biological agents, which are a breakthrough in the therapy of IBD. Among the biological agents currently available in clinical practice are the anti-tumor necrosis factor α (TNF-α) antibodies infliximab, adalimumab, and certolizumab. The effectiveness of anti-TNF-α antibodies in the maintenance therapy of Crohn's disease was confirmed in clinical trials. The anti-TNF-α agents have different routes of administration, but their effectiveness and safety profiles seem to be similar. Evaluation of the safety of long-term anti-TNF-α therapy requires further studies. This article discusses the rules of maintenance therapy in IBD and describes the special role of biological agents and their place in the guidelines on the management of inflammatory bowel disease.
ACCESSION #
52678428

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics